微囊化牛肾上腺嗜铬细胞脊髓蛛网膜下移植治疗慢性疼痛患者的初步观察

Primary study on microencapsulated bovine adrena chromaffin cell xenotransplantation for chronic termial pain

目的 观察海藻酸钠 -聚赖氨酸 -海藻酸钠 (APA)微囊化牛肾上腺嗜铬细胞 (BCC)异种移植对慢性顽固性疼痛患者的镇痛效应、作用持续时间及毒副作用。方法 用Sun氏微囊制作法将BCC包裹于APA微囊内 ,用常规腰穿法将 5ml微囊化BCC(5～ 7)× 10 6悬液注入患者L3～ 5蛛网膜下。结果 2 0例中、重度慢性疼痛患者在 1或 2次注射后 ,疼痛迅速减轻 ,疼痛缓解率为 90 %。在未用任何免疫抑制剂的条件下 ,其中 3例停用镇痛药时间超过 2 0 0d。结论 APA微囊化BCC异种移植于慢性疼痛患者脊髓蛛网膜下 ,可安全、迅速、长时间、有效地发挥镇痛作用。

Objective To study the analgesic effect, the effective duration and the toxic and side effects of Alginate Polylysine Alginate (APA) microencapsulated bovine chromaffin cells (BCC) xenotransplantation on the terminal pain of 20 patients. Methods Sun's microencapsulation method was applied to encapsulate BCC with APA membrane and transplant the microencapsulated BCC(5～7)×10 6 into the subarachnoid space L 3～5 of 20 patients. Results All 20 patients had pain relief rapidly after transplantation. Complete pain relief was shown in 14 cases, dramatic relief in 3 cases, medium relief in 1 case, slight relief in 2 cases. The rate for above medium relief was 90?%. Without any immunosuppressants, 3 patients remained pain free for over 200 days. Obvious toxic and side effects were not found. Conclusions Xenotransplantation of APA microencapsulated BCC into the spinal subarachnoid space of patients with cancer pain can promptly, significantly, safely produce analgesic effect for a long period. Microencapsulated BCC xenotransplantation may provide a unique and effective approach to the treatment of intractable chronic pain in human.